These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29197423)

  • 1. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
    Vanderschaeghe G; Vandenberghe R; Dierickx K
    J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.
    Wang Y; Ren D; Roberts JS; Tamres LK; Lingler JH
    J Prev Alzheimers Dis; 2024; 11(4):958-965. PubMed ID: 39044506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.
    Vanderschaeghe G; Schaeverbeke J; Vandenberghe R; Dierickx K
    Neuroethics; 2017; 10(2):281-297. PubMed ID: 28725289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment.
    Lingler JH; Sereika SM; Butters MA; Cohen AD; Klunk WE; Knox ML; McDade E; Nadkarni NK; Roberts JS; Tamres LK; Lopez OL
    Alzheimers Dement; 2020 Sep; 16(9):1330-1337. PubMed ID: 32588971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial.
    Fruijtier AD; van der Schaar J; van Maurik IS; Zwan MD; Scheltens P; Bouwman F; Pijnenburg YAL; van Berckel BNM; Ebenau J; van der Flier WM; Smets EMA; Visser LNC
    Alzheimers Dement; 2023 Jan; 19(1):285-295. PubMed ID: 35366050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
    Lim YY; Maruff P; Getter C; Snyder PJ
    Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
    de Wilde A; van Buchem MM; Otten RHJ; Bouwman F; Stephens A; Barkhof F; Scheltens P; van der Flier WM
    Alzheimers Res Ther; 2018 Jul; 10(1):72. PubMed ID: 30055660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
    Lingler JH; Butters MA; Gentry AL; Hu L; Hunsaker AE; Klunk WE; Mattos MK; Parker LS; Roberts JS; Schulz R
    J Alzheimers Dis; 2016 Mar; 52(1):17-24. PubMed ID: 27060950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?
    James HJ; Van Houtven CH; Lippmann S; Burke JR; Shepherd-Banigan M; Belanger E; Wetle TF; Plassman BL
    J Alzheimers Dis; 2020; 74(2):625-636. PubMed ID: 32065790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
    Caprioglio C; Ribaldi F; Visser LNC; Minguillon C; Collij LE; Grau-Rivera O; Zeyen P; Molinuevo JL; Gispert JD; Garibotto V; Moro C; Walker Z; Edison P; Demonet JF; Barkhof F; Scheltens P; Alves IL; Gismondi R; Farrar G; Stephens AW; Jessen F; Frisoni GB; Altomare D;
    JAMA Netw Open; 2023 Jan; 6(1):e2250921. PubMed ID: 36637820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    Shepherd-Banigan ME; Ford CB; Smith VA; Belanger E; Wetle TT; Plassman BL; Burke JR; DePasquale N; O'Brien EC; Sorenson C; Van Houtven CH
    J Alzheimers Dis; 2022; 90(2):775-782. PubMed ID: 36189596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.